Skip to main content

2 Healthcare Testing & Diagnostic Stocks Taking Center Stage Ahead of JP Morgan Conference

CORAL GABLES, FL / ACCESSWIRE / January 9, 2018 / This week marks the start of JPMorgan's healthcare conference. Investors will be paying close attention to what is revealed and, certainly, the new trends for 2018 will be discussed. Wall Street rose to a new high at the opening bell on Tuesday, with gains for healthcare stocks extending the New Year rally. This latest move has been powered by expectations of strong quarterly earnings. In fact, jumps in some of the larger healthcare companies in the sector aided in boosting the S&P health sector by 0.7 percent.

One of the developing trends that has come further into the light has been self-diagnosis, early detection, and in-home preventative care. For this reason, some smaller companies have gained investor attention for novel medical technologies that fall in line with this new trend. Both Lexington Biosciences (OTCQB: LXGTF) and Akers Biosciences (NASDAQ: AKER) have seen increased trading activity this week with the kick-off of this year's lead healthcare conference.

Lexington Biosciences ("LXGTF") has increased by more than 90% since early October of 2017. Shares of the cardiovascular self-measurement device company have managed to see highs of $0.4844 within the last 45 days and after the company's recent announcement, it would appear that trading activity continues to remain higher than it was during the last week of December.

Lexington recently announced the delivery of its initial order of HeartSentry devices slated for clinical trials. According to the company, plans are to next initiate commencement of a pilot clinical research study designed to begin gathering the foundational dataset aimed at supporting FDA clearance. For more information on LXGTF, access a full report here.

Similarly, Akers Biosciences, Inc. ("AKER") has also garnered its own attention in the market during recent weeks. Bigger Capital Fund LP has filed a new 13G, reporting 8.0% ownership in Akers. The company recently announced the closing of its previously announced underwritten public offering, for total gross proceeds of $6,900,000. Since making this final announcement, shares of the company have increased by as much as 75% following highs of $0.21 on Tuesday.

The company develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. Akers has a pipeline of diagnostic, testing, and wellness products to offer, including Heparin-Induced Thrombocytopenia and PF4 Antibodies, as well as the BreathScan Lync® reader, an optical scanning device that reads and interprets breath test data. BreathScan Lync® can monitor health data over time, in response to diet, exercise, nutritional supplementation, and/or other regimens.

About TechStockInsider.com:

TechStockInsider.com is owned Midam Ventures, LLC has been compensated an additional $250,000.00 by Ellis Stewart, LLC for a period beginning January 1, 2018 and ending February 1, 2018 to publicly disseminate information about LXGTF. For full disclaimer, click here.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TSI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://TechStockInsider.com

NO WARRANTY

TSI, the Author, and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

Contact:

News@TechStockInsider.com

SOURCE: TechStockInsider.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.